Entrada Therapeutics Inc (TRDA) — Cash Flow-to-Debt Ratio
Entrada Therapeutics Inc (TRDA) has a Cash Flow-to-Debt Ratio of -0.39x as of September 2025, meaning its operating cash flow of $-28.31 Million could theoretically repay 0% of its total liabilities ($72.18 Million) in one year. See Entrada Therapeutics Inc (TRDA) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Entrada Therapeutics Inc Cash Flow-to-Debt Ratio (2019–2024)
Historical debt coverage capacity for Entrada Therapeutics Inc across 6 annual periods. Also explore Entrada Therapeutics Inc (TRDA) net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Entrada Therapeutics Inc (2019–2024)
Year-by-year debt coverage analysis for Entrada Therapeutics Inc. For market capitalisation and broader financial context, see Entrada Therapeutics Inc (TRDA) total market value.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.43x | $-41.56 Million | $97.64 Million | ▼ -169.1% |
| 2023 | 0.62x | $139.80 Million | $226.83 Million | ▲ +126.0% |
| 2022 | -2.37x | $-93.79 Million | $39.50 Million | ▲ +66.8% |
| 2021 | -7.15x | $-50.86 Million | $7.12 Million | ▼ -2276.8% |
| 2020 | -0.30x | $-25.57 Million | $85.02 Million | ▲ +6.0% |
| 2019 | -0.32x | $-10.80 Million | $33.76 Million | — |